Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06562348Phase 2Recruiting

The ctDNA-RECIST Trial Part One

Role: lead

NCT05385250Not ApplicableActive Not Recruiting

Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II

Role: lead

NCT04680260Phase 2Recruiting

OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer

Role: lead

NCT03750175Completed

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Role: lead

NCT03748680Phase 2Unknown

IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer

Role: lead

All 5 trials loaded